ライフサイエンスコーパス: FEV

1 FEV(0.5) and Feno values were significantly associated w

2 FEV(1) at subspecialty pulmonary evaluation within 6.5 y

3 FEV(1) decrease was -25.7 mL/y in the overall population

4 y (FEV(1)% predicted, r = -0.848, P = 0.001; FEV(1)/FVC, r = -0.918, P < 0.001; Kco% predicted, r = -

5 oup M (radiography, P = .005; FVC, P = .011; FEV(1), P = .529).

6 elation between dietary patterns and FEV(1), FEV(1) decline, and respiratory health in a general popu

7 ork personnel with normal pre-September 11th FEV(1) and who presented for subspecialty pulmonary eval

8 expressing the transcription factors NKX2.2, FEV, GATA2 and LMX1B in combination with ASCL1 and NGN2

9 pes (combined P values: COPD, 1.5 x 10(-23); FEV(1)/FVC, 1.5 x 10(-35); FEV(1), 2.2 x 10(-40)).

10 D, 1.5 x 10(-23); FEV(1)/FVC, 1.5 x 10(-35); FEV(1), 2.2 x 10(-40)).

11 FEV(1) above 80%predicted); Group-B (n = 38; FEV(1) below 80% predicted); and Group-LT (n = 20; data

12 ory volume in 1 second (FEV(1)) (r = -0.68), FEV(1)/forced vital capacity (FVC) ratio (r = -0.74) (P

13 Patients with COPD (mean age, 68; FEV(1) 53 +/- 21% predicted) had widespread reduction in

14 -associated declines in lung function (-10.8 FEV(1)% points per log-unit GM-CSF, p<0.001 by linear re

15 Each increased the odds of abnormal FEV(1) at pulmonary evaluation by more than twofold, whe

16 eosinophils was associated with accelerated FEV(1) decrease.

17 Minimal overlap was seen across FEV(1) and asthma control day predictors, suggesting dis

18 hers had received beta carotene had adjusted FEV(1) and FVC values that were similar to those of chil

19 nction by any metric had more rapid adjusted FEV(1) decline.

20 f 0.70 or less after bronchodilators (and an FEV(1) of 70% or less of predicted), and a documented hi

21 workers who had never smoked and who had an FEV(1) below the lower limit of the normal range increas

22 tomatic or exercise-limited patients with an FEV(1) >50% predicted.

23 abilitation for symptomatic patients with an FEV(1) <50% predicted (Grade: strong recommendation, mod

24 L], FVC -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC ratio -0.0012 [95% CI -0.0072 to 0.0047L]).

25 nths, respectively (P = 0.177 and 0.040) and FEV(1) was increased by 148 and 167 ml, respectively (P

26 9586 = -0.31, placebo = -0.17, P = .058) and FEV(1) (GSK679586 = -0.01, placebo = 0.03, P = .276).

27 qualitative COPD and quantitative FEV(1) and FEV(1)/(F)VC phenotypes in two independent large populat

28 The associations of FEV(1) and FEV(1)/FVC ratio decrease with 2.5 million single nucleo

29 ody mass index, 28 +/- 6; ACT, 16 to 19; and FEV(1), 2.5 +/- 0.7 L (86% +/- 20% predicted); exacerbat

30 ody mass index, 28 +/- 6; ACT, 16 to 19; and FEV(1), 2.7 +/- 0.9 L (71% +/- 12% predicted); exacerbat

31 anscriptional interaction between Gata-2 and FEV and a unique marker for new insight into FEV/Pet-1 f

32 walls correlated with FEV(1) (r = -0.60) and FEV(1)/FVC ratio (r = -0.60) (P < .001).

33 outcomes (FEV(1), forced vital capacity, and FEV(1)/forced vital capacity ratio) are proposed as core

34 nists for symptomatic patients with COPD and FEV(1) <60% predicted.

35 or symptomatic patients with stable COPD and FEV(1)<60% predicted (Grade: weak recommendation, modera

36 on between the height-related gene DLEU7 and FEV(1) decrease suggested for nonasthmatic participants

37 Feno and FEV(0.5) values returned to baseline levels within 10 da

38 hniques identified a relation between FM and FEV in girls.

39 sociated with a decline from maximum FVC and FEV(1) (P </= 0.04).

40 d with a slower decline from maximum FVC and FEV(1) (P </= 0.04).

41 consumed >or=4 cups of coffee daily, FVC and FEV(1) were 2%-3% greater than in never or former smoker

42 FVC and FEV(1) were associated with breastfeeding only in childr

43 with vitamin D deficiency (FEV(1), FVC, and FEV(1)/FVC; P </= 0.0002), and longitudinal analysis sho

44 by the expression of Ascl1, Foxa2, Lmx1b and FEV.

45 ssociations between spirometric measures and FEV(1) decline and mortality were determined after adjus

46 te the relation between dietary patterns and FEV(1), FEV(1) decline, and respiratory health in a gene

47 to-moderate COPD (FEV(1) > 50% predicted and FEV(1)/FVC ratio < 0.7) and diagnosed with an exacerbati

48 COPD patients with respiratory symptoms and FEV(1) <60% predicted, ACP, ACCP, ATS, and ERS recommend

49 COPD patients with respiratory symptoms and FEV(1) between 60% and 80% predicted, ACP, ACCP, ATS, an

50 e asthma symptoms, rescue albuterol use, and FEV(1) reversal (P < 0.001, 0.03, and 0.03, respectively

51 e exposure during different time windows and FEV at 8 years was analyzed by linear regression, adjust

52 Airflow obstruction was defined as FEV(1) and its ratio to FVC (FEV(1)/FVC) both less than

53 s assess different manifestations of asthma: FEV(1) (percent predicted), Asthma Quality of Life Quest

54 hold for differential decline was present at FEV(1)/FVC less than 0.65 (P < 0.001) and Z-score less t

55 All patients should have a baseline FEV(1) and DL(CO) measured, and predicted postoperative

56 riostin subgroup, the increase from baseline FEV(1) was 1.6 percentage points higher in the lebrikizu

57 riostin subgroup, the increase from baseline FEV(1) was 8.2 percentage points higher in the lebrikizu

58 Individuals with lower baseline FEV(1)/FVC have more rapid decline and worse mortality.

59 The patients had a mean baseline FEV(1) of 62% of the predicted value; the mean age was 5

60 ipants were stratified into bins of baseline FEV(1) to FVC ratio, using bins of 5%, and separately in

61 At baseline, FEV(1) , PC(20) methacholine or histamine, and PC(20) AM

62 Obstructive patients developed their best FEV(1) earlier after LTx and demonstrated a significant

63 reover, we could find an association between FEV(1) and 25-OHD levels in univariate analysis (P=0.018

64 le, variables found to be predictive of both FEV(1) and severe COPD were age, sex, pack-years of smok

65 Post-bronchodilator FEV (1) (% predicted) in the subjects with asthma was 71

66 ociated with an impaired post-bronchodilator FEV (1) , which might be partly responsible for the deve

67 I -0.086 to -0.0009) and post-bronchodilator FEV(1)/FVC ratio (adj.

68 relates to the ratio of post-bronchodilator FEV(1)/FVC, but only among those with atopic sensitizati

69 or rs7937 and rs2604894), pre-bronchodilator FEV(1) (P = 0.08 and 0.04) and severe (GOLD 3&4) COPD (P

70 lume in 1 second over forced vital capacity (FEV(1)/FVC) was measured in 4,267 nonasthmatic SAPALDIA

71 (1)) and its ratio to forced vital capacity (FEV(1)/FVC), an indicator of airflow obstruction.

72 volume in 1 second to forced vital capacity (FEV(1):FVC ratio; pulmonary), hemoglobin concentration (

73 Group-N (n = 35; control, FEV(1) above 80%predicted); Group-B (n = 38; FEV(1) belo

74 ometrically confirmed mild-to-moderate COPD (FEV(1) > 50% predicted and FEV(1)/FVC ratio < 0.7) and d

75 Fifteen men with COPD (FEV(1) = 32.2 +/- 12.0% predicted; FEV(1)/FVC = 31.6 +/-

76 randomized design, eight patients with COPD (FEV(1), 67 +/- 8% predicted) completed a constant work-r

77 c Obstructive Lung Disease (GOLD) criterion (FEV(1)/FVC < 0.70) and Quanjer reference equation (FEV(1

78 n relation to asthma (P = .03) and decreased FEV(1)/forced vital capacity ratio (P = .03).

79 a higher prevalence of asthma and decreased FEV(1)/forced vital capacity ratio.

80 transplantation, had significantly decreased FEV(1), increased total lung capacity, and donor organ w

81 n current smokers with vitamin D deficiency (FEV(1), FVC, and FEV(1)/FVC; P </= 0.0002), and longitud

82 er, the regulatory mechanisms that determine FEV expression are poorly understood.

83 as associated (P = .048) with a differential FEV(1) response favoring LABA over ICS step-up therapy,

84 ginally (P = .053) related to a differential FEV(1) response favoring LTRA over LABA step-up therapy.

85 untranslated region are sufficient to direct FEV transgene expression to embryonic 5-HT neurons, alth

86 /FVC < 0.70) and Quanjer reference equation (FEV(1)/FVC < lower limit of normal [LLN]), and categoriz

87 We evaluated FEV(1) , bronchial hyper-responsiveness (PC(20) ) to eit

88 ospitalization, time to second exacerbation, FEV(1), quality of life, and death.

89 0.7 L (86% +/- 20% predicted); exacerbation: FEV(1), 1.7 +/- 0.4 L (60% +/- 17%) (P < .001); recovery

90 0.9 L (71% +/- 12% predicted); exacerbation: FEV(1), 1.7 +/- 0.6 L (54% +/- 19%) (P< .006); recovery:

91 eported ever diagnosed asthma were excluded (FEV(1) -0.011L, [95% CI -0.05 to 0.028L], FVC -0.012L [9

92 ry volume in the first second of expiration (FEV(1)) of at least 50% predicted, and negative respirat

93 inear (P < .001): at low levels of exposure, FEV(1) increased by 13 mL/joint-year (95% CI, 6.4 to 20;

94 For FEV(1)/FVC ratio similar findings were observed among ad

95 ormer smokers, <0.001 for FVC and <0.001 for FEV(1)).

96 in never smokers, 0.04 for FVC and 0.07 for FEV(1); in former smokers, <0.001 for FVC and <0.001 for

97 Longitudinal analyses for FEV(1) and FVC yielded results in the direction opposite

98 validation sample, the predictive model for FEV(1) explained 50% of the variance in FEV(1), and the

99 berrantly distributed, suggesting a role for FEV/Pet-1 in their midline organization.

100 The slope for FEV(1) was -2.2 mL/joint-year (95% CI, -4.6 to 0.3; P =

101 ial inflammation (FeNO, ppb), lung function (FEV(1)%) and bronchial hyper-responsiveness (BHR) (dose-

102 was defined as FEV(1) and its ratio to FVC (FEV(1)/FVC) both less than their respective lower limits

103 rcent predicted forced vital capacity (FVC), FEV(1)/FVC ratio, and PC(20) were observed.

104 Post-bronchodilator FVC, FEV(1), peak expiratory flow (PEF), forced midexpiratory

105 but not CRP, independently predicted greater FEV(1)/FVC decline in the elderly.

106 Mean changes in 4-10 h %FEV(1) were as follows: -21.08 (placebo), -14.30 (VI), -

107 Mean changes in 0-2 h %FEV(1) were as follows: -28.05 (placebo), -23.10 (VI), -

108 6.5 years defined disease status; cases had FEV(1) less than lower limit of normal, whereas control

109 imit of normal, whereas control subjects had FEV(1) greater than or equal to lower limit of normal.

110 survival than group C, in spite of a higher FEV(1) level.

111 GP IgE was associated with a higher FEV(1) percent predicted value, and enterotoxin IgE was

112 Altered expression of the human FEV (fifth Ewing variant) ETS transcription factor gene

113 not the two placebo interventions, improved FEV(1) in these patients with asthma, albuterol provided

114 Prednisone significantly improved FEV(1) percentages in SS asthmatic patients (mean +/- SE

115 h a clinically significant decline (-13%) in FEV(1) in both cohorts of asthmatics among males but not

116 nificant (</=.006) decrease from baseline in FEV(1) (L) during exacerbation and similar increase (</=

117 The difference in the change in FEV(1) between the azithromycin and placebo groups was 0

118 n in airway hyperresponsiveness or change in FEV(1) but have suggested an improvement in quality of l

119 tween-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approx

120 The primary endpoint was absolute change in FEV(1) from baseline in treated versus control groups, a

121 In the FA population, the mean change in FEV(1) was 7.1% on OC000459 compared with 4.3% on placeb

122 The primary outcome was change in FEV(1).

123 years posttransplant mean annual decline in FEV(1) % was lower (0.74%; p = 0.04) compared with the p

124 alysis showed more rapid rates of decline in FEV(1) (P = 0.023) per pack-year of smoking in subjects

125 significantly reduce the rate of decline in FEV(1).

126 d Trade Center dust led to large declines in FEV(1) for FDNY rescue workers during the first year.

127 tifies patients with large acute declines in FEV(1)%, possibly providing a laboratory-based objective

128 ciation study on the age-related decrease in FEV(1) and its ratio to forced vital capacity (FVC) stra

129 hood was associated with large decrements in FEV(1) among participants with a mean age of 66 years (-

130 ipe-years were associated with decrements in FEV(1), and cigar-years were associated with decrements

131 .009), with only a borderline difference in FEV(1) for subgroups A versus C (P = .031).

132 ere was a twofold to threefold difference in FEV(1) response for those subjects homozygous for the wi

133 Resource Project, we analyzed differences in FEV(1) in response to inhaled corticosteroids in 418 whi

134 f methacholine that results in a 20% drop in FEV(1)) of 8 mg/mL.

135 were significantly associated with falls in FEV(1) (rho = -0.20, P = 0.032).

136 d less corticosteroid-induced improvement in FEV(1) %predicted in obese patients than in lean patient

137 The smaller improvement in FEV(1) and sputum eosinophils suggests a worse corticost

138 The treated group had a mean improvement in FEV(1) of 105 ml (8.2% above baseline).

139 treated group had a relative improvement in FEV(1) of 3.75% (P = 0.029) versus the control group.

140 Relative improvements in FEV(1) % predicted achieved by the AZLI run-in were main

141 I maintained the substantial improvements in FEV(1) % predicted achieved during the AZLI run-in and w

142 = 5% at 6 months had greater improvements in FEV(1) (11.53 +/- 9.31 vs. 6.58 +/- 8.68%; P < 0.0001),

143 Mean absolute improvements in FEV(1) in the tiotropium group were maintained throughou

144 ), and BDR (>/=200 mL and >/=12% increase in FEV(1) or forced vital capacity) was present in 20 (9.0%

145 At week 12, the mean increase in FEV(1) was 5.5 percentage points higher in the lebrikizu

146 udy, albuterol resulted in a 20% increase in FEV(1), as compared with approximately 7% with each of t

147 There was little or no recovery in FEV(1) during the subsequent 6 years, with a mean annual

148 tion in FEV(1) (PD(20)) and the reduction in FEV(1) (%) after a standardized treadmill test were used

149 e methacholine dose causing 20% reduction in FEV(1) (PD(20)) and the reduction in FEV(1) (%) after a

150 6 years, with a mean annualized reduction in FEV(1) of 25 ml per year for firefighters and 40 ml per

151 for FEV(1) explained 50% of the variance in FEV(1), and the model for severe COPD exhibited excellen

152 econdary and exploratory end points included FEV(1), symptom scores, rescue short-acting beta-agonist

153 ldren of mothers with asthma, with increased FEV(1) and FVC.

154 hree groups were formed according to initial FEV(1).

155 he phenomenon did not correlate with initial FEV(1) (%predicted) or age.

156 FEV and a unique marker for new insight into FEV/Pet-1 function in 5-HT neuron development.

157 ei and thus provided additional insight into FEV/Pet-1 function.

158 Reduced lung function, such as a low FEV(1) , represents bronchial constriction, what do the

159 soy and cereal) was associated with a lower FEV(1) (fifth compared with first quintile: -94.4 mL; 95

160 seems independently associated with a lower FEV(1) and more severe B-grade rejections.

161 enterotoxin IgE was associated with a lower FEV(1) percent predicted value.

162 , 1.5-4.9; P = 0.001) and atopy, and a lower FEV(1)/FVC in cases.

163 as a whole, atopy was associated with lower FEV(1) (adjusted difference -0.068L, 95% confidence inte

164 of African ancestry is associated with lower FEV(1) and forced vital capacity (FVC) in Puerto Rican c

165 lifetime, was linearly associated with lower FEV(1) and FVC.

166 OH]D) levels have been associated with lower FEV(1), impaired immunologic control, and increased airw

167 eroid sensitive (SS) based on change in lung FEV(1) percentage after 7 days of oral prednisone.

168 d CS requirements and improved or maintained FEV(1) despite lower CS doses.

169 tudy assessed whether FTI/placebo maintained FEV(1) % predicted improvements achieved following a 28-

170 ption factor ETS-5, an ortholog of mammalian FEV/Pet1, controls satiety-induced quiescence.

171 atients (mean age, 65+/-8 years) with a mean FEV(1) of 1.32+/-0.44 liters after bronchodilation (48%

172 nto or relapses during adulthood with a mean FEV(1) of about 10% of predicted value less than their p

173 At baseline, patients had a mean FEV(1) that was 65% of the predicted value and were taki

174 Mean age was 32 years and mean FEV(1) was 49% predicted at screening.

175 rth American patients with severe COPD (mean FEV(1) 1.12L; 40% of predicted), mean 25(OH)D was 25.7 +

176 was 153 ml, or approximately 11% of the mean FEV(1) at enrollment.

177 points were the rate of decline in the mean FEV(1) before and after bronchodilation beginning on day

178 wo groups in the rate of decline in the mean FEV(1) before and after bronchodilation were not signifi

179 In the first year, the mean FEV(1) decreased significantly for all workers, more for

180 ximal inhaled corticosteroid treatment (mean FEV(1), 60% of predicted value; mean Asthma Control Ques

181 o, the late change (4-10 h) in weighted mean FEV(1) was -0.466 l (-0.589; -0.343) and -0.298 l (-0.41

182 ce of GSK2190915 vs. placebo for the minimum FEV(1) EAR was 0.408 L (0.205, 0.611).

183 ce of GSK2190915 vs. placebo for the minimum FEV(1) LAR was 0.229 L (0.041, 0.417).

184 nverse association of FEV(1) and FVC but not FEV(1)/FVC with mortality.

185 ality rate and strong inverse association of FEV(1) and FVC but not FEV(1)/FVC with mortality.

186 The associations of FEV(1) and FEV(1)/FVC ratio decrease with 2.5 million si

187 e investigated the cis-regulatory control of FEV to begin to identify the upstream transcription fact

188 ND MAIN RESULTS: Group-N's yearly decline of FEV(1), FEF(25-75), and FEF(25-75)/FVC were similar and

189 fore lung transplantation and independent of FEV(1) (%predicted), FEV(1) decline rate, or age, an abr

190 Comparable numbers of FEV-LacZ-positive cells were detected in Pet-1(+/-) and

191 tory volume in 1 s (FEV(1)) and the ratio of FEV(1) to forced vital capacity (FVC) in the SpiroMeta c

192 or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less.

193 1 and identified associations with FEV(1) or FEV(1)/FVC and common variants at five additional loci:

194 Spirometric outcomes (FEV(1), forced vital capacity, and FEV(1)/forced vital c

195 ity [VC] <0.7) and a nonobstructive pattern (FEV(1):VC >/=0.7) in pulmonary function tests 3 months a

196 4 weeks, the mean (+/-SE) change in the peak FEV(1) from baseline was greater with tiotropium than wi

197 children whose mothers had received placebo (FEV(1), 14 ml higher with beta carotene; 95% CI, -24 to

198 children whose mothers had received placebo (FEV(1), 46 ml higher with vitamin A; 95% confidence inte

199 Postbronchodilator FEV(1) was also dependent on exacerbations, age of onset

200 7 to -69 mL; P< .001) and postbronchodilator FEV(1) (-152 mL; 95% CI, -210 to -94 mL; P< .001) and FV

201 for prebronchodilator and postbronchodilator FEV(1) (change for each 20% increment in African ancestr

202 and prebronchodilator and postbronchodilator FEV(1) also are core outcomes for study population chara

203 hilia was associated with postbronchodilator FEV(1) in asthmatic patients.

204 een 25-OHD levels and the peak postoperative FEV(1) (P=0.021 in multivariate analysis).

205 DL(CO) measured, and predicted postoperative FEV(1) and DL(CO) calculated to assist with risk predict

206 Prebronchodilator FEV(1) values remained stable between years 1 and 5 afte

207 am with covariates of age, prebronchodilator FEV(1)% predicted, time in study, prior hospitalizations

208 In a pooled analysis, prebronchodilator FEV(1) increased by 48 mL with roflumilast compared with

209 amin D-deficient group and prebronchodilator FEV(1) increased by 330 ml in the vitamin D insufficienc

210 costeroid treatment group, prebronchodilator FEV(1) increased from randomization to 12 months by 140

211 me measures were change in prebronchodilator FEV(1), bronchodilator response, and PC(20) from enrollm

212 ntly associated with lower prebronchodilator FEV(1) (-105 mL; 95% CI, -159 to -51 mL; P< .001) and FV

213 ized by severity (>/= 80% and <80% predicted FEV(1) for stage I and stage II+, respectively).

214 ore (difference between actual and predicted FEV(1)/FVC, normalized to SD of predicted FEV(1)/FVC).

215 through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivac

216 ed FEV(1)/FVC, normalized to SD of predicted FEV(1)/FVC).

217 ipants differing by 10% in percent predicted FEV(1) (P < .001) and by 0.5 points in Asthma Control Qu

218 were associated with lower percent predicted FEV(1) (P= .02) and lower percent predicted FVC (P= .008

219 as associated with a lower percent predicted FEV(1) in the SARP cohort (P= .005), the CSGA cohort (P=

220 esence of atopy, and lower percent predicted FEV(1) were associated with a positive test result.

221 ty (based on the percentage of the predicted FEV(1)) in 4 to 5% of participants.

222 tion and independent of FEV(1) (%predicted), FEV(1) decline rate, or age, an abrupt rapid dysanapsis

223 ith COPD (FEV(1) = 32.2 +/- 12.0% predicted; FEV(1)/FVC = 31.6 +/- 7.1%; exercise oxygen saturation a

224 and tested qualitative COPD and quantitative FEV(1) and FEV(1)/(F)VC phenotypes in two independent la

225 .56]; P = 0.41), nor did exacerbation rates, FEV(1), hospitalization, quality of life, and death.

226 /- 0.4 L (60% +/- 17%) (P < .001); recovery: FEV(1), 2.5 +/- 0.7 L (85% +/- 13%) (P < .001).

227 +/- 0.6 L (54% +/- 19%) (P< .006); recovery: FEV(1), 2.7 +/- 0.9 L (70% +/- 14%) (P= .002).

228 t year of life was associated with a reduced FEV(1) of -59.3 ml (95% confidence interval, -113 to -5.

229 elation coefficient (r(2) = 0.8) and reduced FEV(1) (r(2) = -0.26).

230 upstream transcription factors that restrict FEV expression to 5-HT neurons.

231 nchodilator forced expiratory volume in 1 s (FEV(1) ); eosinophilic airway inflammation was assessed

232 = 0.01) and forced expiratory volume in 1 s (FEV(1)) (P </= 0.05) (maximum across years 0-10) in line

233 ase fall in forced expiratory volume in 1 s (FEV(1)) after whole-lung inhalation of the Ag that was s

234 nchodilator forced expiratory volume in 1 s (FEV(1)) and the rate of exacerbations that were moderate

235 iation with forced expiratory volume in 1 s (FEV(1)) and the ratio of FEV(1) to forced vital capacity

236 ovements in forced expiratory volume in 1 s (FEV(1)) from baseline, average weight gain, concentratio

237 nchodilator forced expiratory volume in 1 s (FEV(1)) in a subset of subjects with uncontrolled asthma

238 in minimum forced expiratory volume in 1 s (FEV(1)) of -1.091 l (95% CI: -1.344; -0.837) following p

239 atterns and forced expiratory volume in 1 s (FEV(1)) or respiratory symptoms.

240 a ratio of forced expiratory volume in 1 s (FEV(1)) to forced vital capacity of 0.70 or less after b

241 D [x +/- SD forced expiratory volume in 1 s (FEV(1)): 34.5 +/- 16.5] and 104 healthy, age-matched con

242 ng spirometry [forced expired volume in 1 s (FEV)]; and 3) compare findings with those from more comm

243 The mean (SD) FEV(1) at baseline and 168 days were 2.13 (0.85) L and 2

244 uction in forced expiratory volume in 1 sec (FEV(1)) or forced vital capacity (FVC), or both, after a

245 function (forced expiratory volume in 1 sec [FEV(1)] %predicted) were measured in 131 lung transplant

246 tructive (forced expiratory volume in 1 sec [FEV(1)]: vital capacity [VC] <0.7) and a nonobstructive

247 0.75), forced expiratory volume in 1 second (FEV(1)) (r = -0.68), FEV(1)/forced vital capacity (FVC)

248 had a forced expiratory volume in 1 second (FEV(1)) and a forced vital capacity (FVC) that were sign

249 ted to forced expiratory volume in 1 second (FEV(1)) and forced vital capacity in the CARDIA cohort.

250 ls for forced expiratory volume in 1 second (FEV(1)) and the presence of severe COPD using demographi

251 ilator forced expiratory volume in 1 second (FEV(1)) from baseline to week 12.

252 with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio

253 ilator forced expiratory volume in 1 second (FEV(1)) of 80% or less of the predicted value, and had a

254 ed the forced expiratory volume in 1 second (FEV(1)) of both active and retired FDNY rescue workers o

255 argest forced expiratory volume in 1 second (FEV(1)) to forced vital capacity (FVC) ratio, those with

256 Forced expiratory volume in 1 second (FEV(1)) was <80% predicted in 45%, and 47% had subtle CX

257 aximum forced expiratory volume in 1 second (FEV(1)) was measured, and patients' self-reported improv

258 lower forced expiratory volume in 1 second (FEV(1)), was associated with poorer Short Physical Perfo

259 pe) in forced expiratory volume in 1 second (FEV(1)).

260 dicted forced expiratory volume in 1 second (FEV(1)).

261 C) and forced expiratory volume in 1 second (FEV(1)).

262 ine in forced expiratory volume in 1 second (FEV(1))/forced vital capacity (FVC) ratio with increasin

263 orced expiratory volume in the first second (FEV(1)) and its ratio to forced vital capacity (FEV(1)/F

264 orced expiratory volume during first second (FEV(1)) or carbon monoxide diffusing capacity (DL(CO)),

265 ilator forced expiratory volume in 1 second [FEV(1)]) in more than 8300 subjects in seven cohorts tha

266 dicted forced expiratory volume in 1 second [FEV(1)], percentage of predicted forced vital capacity [

267 eas forced expiratory volume at 0.5 seconds (FEV(0.5)) significantly decreased compared with baseline

268 the other site is required for serotonergic FEV transgene expression.

269 orrelated with measures of disease severity (FEV(1)% predicted, r = -0.848, P = 0.001; FEV(1)/FVC, r

270 Children with CF underwent spirometry (FEV).

271 In the 26-week open-label extension study, FEV(1) was maintained in the original treated group, and

272 d Trade Center dust exposure with subsequent FEV(1).

273 The FEV(1) was significantly lower in the deficient group co

274 years were associated with decrements in the FEV(1)-FVC ratio.

275 uences extending only 275 bp upstream of the FEV 5' untranslated region are sufficient to direct FEV

276 During the treatment period, the FEV(1) slope was -12+/-2 ml per month in the placebo gro

277 in girls was positively associated with the FEV percentage predicted.

278 intervention effects may be modeled through FEV(1)% predicted to estimate hospitalizations, ED visit

279 rphism in HTR4, a gene previously related to FEV(1)/FVC, achieved genome-wide statistical significanc

280 The predose (trough) FEV(1) also improved in trials 1 and 2 with tiotropium,

281 Unexpectedly, FEV-LacZ transgenes enabled determination of 5-HT neuron

282 function measure--forced expiratory volume (FEV(1)) % of predicted value.

283 PID1 and HTR4) and one locus associated with FEV(1) (INTS12-GSTCD-NPNT) at or near genome-wide signif

284 whether African ancestry is associated with FEV(1) and FVC using linear regression.

285 ation between SNPs that were associated with FEV(1) and the time to the onset of COPD.

286 ic inflammation in sputum is associated with FEV(1) decrease in patients with severe asthma and wheth

287 9 [-82A-->G]) was positively associated with FEV(1) in a combined analysis of children with asthma an

288 We identified eight loci associated with FEV(1)/FVC (HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A, PTC

289 king signal, TUSC3, which is associated with FEV(1)/FVC ratio decrease in asthmatic participants (P =

290 or = 0.04) and six SNPs were associated with FEV(1)/VC (0.02 < or = P < or = 0.03) from family-based

291 eavy marijuana use, the net association with FEV(1) was not significantly different from baseline, an

292 cus at 4q31 and identified associations with FEV(1) or FEV(1)/FVC and common variants at five additio

293 th thickened bronchial walls correlated with FEV(1) (r = -0.60) and FEV(1)/FVC ratio (r = -0.60) (P <

294 phoresis, and was negatively correlated with FEV(1) over the full range of values investigated.

295 I and laminin in asthma were correlated with FEV(1) reversibility (r = -0.65, P = 0.01; r = -0.54, P

296 Nineteen asthmatic patients with FEV(1) of less than 80% of predicted value were classifi

297 conducted to investigate these patterns with FEV(1) or respiratory health.

298 ects with poorly controlled asthma had worse FEV(1), fraction of exhaled nitric oxide measured at 200

299 Lung function remained stable until 4 years (FEV(1) % predicted; pretransplant 48.4% vs. 45.9%, 4 yea

300 even healthy subjects (age = 38 +/- 6 years, FEV = 104 +/- 7% predicted) underwent magnetic resonance